Division of Surgery and Interventional Science, University College London, London, UK.
Department of Urology, University College London Hospital, London, UK.
BJU Int. 2019 Jan;123(1):74-81. doi: 10.1111/bju.14459. Epub 2018 Aug 29.
To determine the diagnostic accuracy of urinary cytology to diagnose bladder cancer and upper tract urothelial cancer (UTUC) as well as the outcome of patients with a positive urine cytology and normal haematuria investigations in patients in a multicentre prospective observational study of patients investigated for haematuria.
The DETECT I study (clinicaltrials.gov NCT02676180) recruited patients presenting with haematuria following referral to secondary case at 40 hospitals. All patients had a cystoscopy and upper tract imaging (renal bladder ultrasound [RBUS] and/ or CT urogram [CTU]). Patients, where urine cytology were performed, were sub-analysed. The reference standard for the diagnosis of bladder cancer and UTUC was histological confirmation of cancer. A positive urine cytology was defined as a urine cytology suspicious for neoplastic cells or atypical cells.
Of the 3 556 patients recruited, urine cytology was performed in 567 (15.9%) patients from nine hospitals. Median time between positive urine cytology and endoscopic tumour resection was 27 (IQR: 21.3-33.8) days. Bladder cancer was diagnosed in 39 (6.9%) patients and UTUC in 8 (1.4%) patients. The accuracy of urinary cytology for the diagnosis of bladder cancer and UTUC was: sensitivity 43.5%, specificity 95.7%, positive predictive value (PPV) 47.6% and negative predictive value (NPV) 94.9%. A total of 21 bladder cancers and 5 UTUC were missed. Bladder cancers missed according to grade and stage were as follows: 4 (19%) were ≥ pT2, 2 (9.5%) were G3 pT1, 10 (47.6%) were G3/2 pTa and 5 (23.8%) were G1 pTa. High-risk cancer was confirmed in 8 (38%) patients. There was a marginal improvement in sensitivity (57.7%) for high-risk cancers. When urine cytology was combined with imaging, the diagnostic performance improved with CTU (sensitivity 90.2%, specificity 94.9%) superior to RBUS (sensitivity 66.7%, specificity 96.7%). False positive cytology results were confirmed in 22 patients, of which 12 (54.5%) had further invasive tests and 5 (22.7%) had a repeat cytology. No cancer was identified in these patients during follow-up.
Urine cytology will miss a significant number of muscle-invasive bladder cancer and high-risk disease. Our results suggest that urine cytology should not be routinely performed as part of haematuria investigations. The role of urine cytology in select cases should be considered in the context of the impact of a false positive result leading to further potentially invasive tests conducted under general anaesthesia.
确定尿细胞学诊断膀胱癌和上尿路尿路上皮癌(UTUC)的诊断准确性,以及在多中心前瞻性观察性血尿研究中,对尿液细胞学检查阳性但血尿检查正常的患者的治疗结果。
DETECT I 研究(clinicaltrials.gov NCT02676180)招募了 40 家医院转诊至二级医院的血尿患者。所有患者均进行了膀胱镜检查和上尿路影像学检查(肾膀胱超声[RBUS]和/或 CT 尿路造影[CTU])。对进行尿液细胞学检查的患者进行了亚分析。膀胱癌和 UTUC 的诊断标准为组织学证实癌症。尿液细胞学检查阳性定义为尿液细胞学检查可疑为肿瘤细胞或非典型细胞。
在招募的 3556 名患者中,9 家医院的 567 名(15.9%)患者进行了尿液细胞学检查。阳性尿液细胞学检查与内镜肿瘤切除术之间的中位时间为 27 天(IQR:21.3-33.8)。39 名(6.9%)患者诊断为膀胱癌,8 名(1.4%)患者诊断为 UTUC。尿细胞学检查诊断膀胱癌和 UTUC 的准确性为:敏感性 43.5%,特异性 95.7%,阳性预测值(PPV)47.6%和阴性预测值(NPV)94.9%。总共漏诊了 21 例膀胱癌和 5 例 UTUC。根据分级和分期漏诊的膀胱癌如下:4 例(19%)≥pT2,2 例(9.5%)为 G3 pT1,10 例(47.6%)为 G3/2 pTa,5 例(23.8%)为 G1 pTa。8 例(38%)患者证实为高危癌症。高危癌症的敏感性略有提高(57.7%)。当尿液细胞学检查与影像学检查相结合时,CTU 的诊断性能有所提高(敏感性 90.2%,特异性 94.9%)优于 RBUS(敏感性 66.7%,特异性 96.7%)。22 例患者的细胞学检查结果呈假阳性,其中 12 例(54.5%)进行了进一步的有创检查,5 例(22.7%)进行了重复细胞学检查。在这些患者的随访中未发现癌症。
尿细胞学检查将漏诊大量肌层浸润性膀胱癌和高危疾病。我们的结果表明,尿细胞学检查不应作为血尿检查的常规检查。在考虑到假阳性结果导致潜在的全身麻醉下进行的有创检查的情况下,应根据其对假阳性结果的影响,考虑在特定情况下尿细胞学检查的作用。